{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T13:59:03Z","timestamp":1789567143304,"version":"build-2803163510"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T00:00:00Z","timestamp":1702512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Pain Headache Rep"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s11916-023-01196-1","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T08:02:42Z","timestamp":1702540962000},"page":"109-118","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phytocannabinoids for the Treatment of Neuropathic Pain: A Scoping Review of Randomised Controlled Trials Published Between 2012 and 2023"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-5888-4641","authenticated-orcid":false,"given":"Marc","family":"Lewis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5178-355X","authenticated-orcid":false,"given":"Saeid","family":"Baroutian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7553-2613","authenticated-orcid":false,"given":"Sara M.","family":"Hanning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,14]]},"reference":[{"issue":"1","key":"1196_CR1","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1152\/physrev.00045.2019","volume":"101","author":"NB Finnerup","year":"2021","unstructured":"Finnerup NB, Kuner R, Jensen TS. Neuropathic pain: from mechanisms to treatment. Physiol Rev. 2021;101(1):259\u2013301.","journal-title":"Physiol Rev"},{"key":"1196_CR2","volume":"12","author":"RMP Campos","year":"2021","unstructured":"Campos RMP, et al. Cannabinoid therapeutics in chronic neuropathic pain: from animal research to human treatment. Front Physiol. 2021;12: 785176.","journal-title":"Front Physiol"},{"issue":"4","key":"1196_CR3","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.pain.2013.11.013","volume":"155","author":"O van Hecke","year":"2014","unstructured":"van Hecke O, et al. Neuropathic pain in the general population: a systematic review of epidemiological studies. Pain. 2014;155(4):654\u201362.","journal-title":"Pain"},{"issue":"1","key":"1196_CR4","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40263-021-00879-w","volume":"36","author":"F Petzke","year":"2022","unstructured":"Petzke F, et al. Cannabis-based medicines and medical cannabis for chronic neuropathic pain. CNS Drugs. 2022;36(1):31\u201344.","journal-title":"CNS Drugs"},{"key":"1196_CR5","doi-asserted-by":"crossref","first-page":"205873841983838","DOI":"10.1177\/2058738419838383","volume":"33","author":"E Cavalli","year":"2019","unstructured":"Cavalli E, et al. The neuropathic pain: an overview of the current treatment and future therapeutic approaches. Int J Immunopathol Pharmacol. 2019;33:2058738419838383.","journal-title":"Int J Immunopathol Pharmacol"},{"issue":"2","key":"1196_CR6","volume":"14","author":"DD Mitsikostas","year":"2022","unstructured":"Mitsikostas DD, et al. Neuropathic pain in neurologic disorders: a narrative review. Cureus. 2022;14(2): e22419.","journal-title":"Cureus"},{"issue":"6","key":"1196_CR7","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s11916-017-0629-5","volume":"21","author":"K Meacham","year":"2017","unstructured":"Meacham K, et al. Neuropathic pain: central vs. peripheral mechanisms. Curr Pain Headache Rep. 2017;21(6):28.","journal-title":"Curr Pain Headache Rep"},{"key":"1196_CR8","unstructured":"bpacnz Ltd, Managing patients with neuropathic pain. Best Practice. 2016;(75):20\u201330."},{"issue":"3","key":"1196_CR9","doi-asserted-by":"crossref","first-page":"60","DOI":"10.18773\/austprescr.2018.022","volume":"41","author":"BP Murnion","year":"2018","unstructured":"Murnion BP. Neuropathic pain: current definition and review of drug treatment. Aust Prescr. 2018;41(3):60\u20133.","journal-title":"Aust Prescr"},{"issue":"6","key":"1196_CR10","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/papr.12014","volume":"13","author":"R Rauck","year":"2013","unstructured":"Rauck R, et al. A randomized, controlled trial of gabapentin enacarbil in subjects with neuropathic pain associated with diabetic peripheral neuropathy. Pain Pract. 2013;13(6):485\u201396.","journal-title":"Pain Pract"},{"issue":"2","key":"1196_CR11","first-page":"e78","volume":"64","author":"GM Allan","year":"2018","unstructured":"Allan GM, et al. Systematic review of systematic reviews for medical cannabinoids: pain, nausea and vomiting, spasticity, and harms. Can Fam Physician. 2018;64(2):e78\u201394.","journal-title":"Can Fam Physician"},{"issue":"6","key":"1196_CR12","doi-asserted-by":"crossref","first-page":"479","DOI":"10.17245\/jdapm.2021.21.6.479","volume":"21","author":"B Sainsbury","year":"2021","unstructured":"Sainsbury B, et al. Efficacy of cannabis-based medications compared to placebo for the treatment of chronic neuropathic pain: a systematic review with meta-analysis. J Dent Anesth Pain Med. 2021;21(6):479\u2013506.","journal-title":"J Dent Anesth Pain Med"},{"issue":"13","key":"1196_CR13","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1111\/1471-0528.15199","volume":"125","author":"E Hariton","year":"2018","unstructured":"Hariton E, Locascio JJ. Randomised controlled trials - the gold standard for effectiveness research: study design: randomised controlled trials. BJOG. 2018;125(13):1716.","journal-title":"BJOG"},{"issue":"1","key":"1196_CR14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"AR Jadad","year":"1996","unstructured":"Jadad AR, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1\u201312.","journal-title":"Control Clin Trials"},{"issue":"4","key":"1196_CR15","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1002\/sim.4780080408","volume":"8","author":"GA Colditz","year":"1989","unstructured":"Colditz GA, Miller JN. Mosteller F How study design affects outcomes in comparisons of therapy. I: Medical. Stat Med. 1989;8(4):441\u201354.","journal-title":"Stat Med"},{"issue":"2","key":"1196_CR16","doi-asserted-by":"crossref","first-page":"156","DOI":"10.2522\/ptj.20070147","volume":"88","author":"SA Olivo","year":"2008","unstructured":"Olivo SA, et al. Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther. 2008;88(2):156\u201375.","journal-title":"Phys Ther"},{"issue":"7","key":"1196_CR17","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jpain.2015.03.008","volume":"16","author":"MS Wallace","year":"2015","unstructured":"Wallace MS, et al. Efficacy of inhaled cannabis on painful diabetic neuropathy. J Pain. 2015;16(7):616\u201327.","journal-title":"J Pain"},{"issue":"8","key":"1196_CR18","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1002\/ejp.1605","volume":"24","author":"S Almog","year":"2020","unstructured":"Almog S, et al. The pharmacokinetics, efficacy, and safety of a novel selective-dose cannabis inhaler in patients with chronic pain: a randomized, double-blinded, placebo-controlled trial. Eur J Pain. 2020;24(8):1505\u201316.","journal-title":"Eur J Pain"},{"key":"1196_CR19","doi-asserted-by":"crossref","first-page":"587","DOI":"10.2147\/JPR.S113138","volume":"9","author":"BL Wilsey","year":"2016","unstructured":"Wilsey BL, et al. A preliminary evaluation of the relationship of cannabinoid blood concentrations with the analgesic response to vaporized cannabis. J Pain Res. 2016;9:587\u201398.","journal-title":"J Pain Res"},{"issue":"10","key":"1196_CR20","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/j.pain.2012.06.024","volume":"153","author":"C Toth","year":"2012","unstructured":"Toth C, et al. An enriched-enrolment, randomized withdrawal, flexible-dose, double-blind, placebo-controlled, parallel assignment efficacy study of nabilone as adjuvant in the treatment of diabetic peripheral neuropathic pain. Pain. 2012;153(10):2073\u201382.","journal-title":"Pain"},{"issue":"2","key":"1196_CR21","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/j.jpain.2012.10.009","volume":"14","author":"B Wilsey","year":"2013","unstructured":"Wilsey B, et al. Low-dose vaporized cannabis significantly improves neuropathic pain. J Pain. 2013;14(2):136\u201348.","journal-title":"J Pain"},{"issue":"14","key":"1196_CR22","doi-asserted-by":"crossref","first-page":"e1285","DOI":"10.1212\/WNL.0000000000006293","volume":"91","author":"L Weizman","year":"2018","unstructured":"Weizman L, et al. Cannabis analgesia in chronic neuropathic pain is associated with altered brain connectivity. Neurology. 2018;91(14):e1285\u201394.","journal-title":"Neurology"},{"issue":"9","key":"1196_CR23","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1016\/j.clinthera.2017.01.016","volume":"40","author":"G van Amerongen","year":"2018","unstructured":"van Amerongen G, et al. Effects on spasticity and neuropathic pain of an oral formulation of \u03b49-tetrahydrocannabinol in patients withprogressive multiple sclerosis. Clin Ther. 2018;40(9):1467\u201382.","journal-title":"Clin Ther"},{"key":"1196_CR24","doi-asserted-by":"crossref","unstructured":"\u2022 Schimrigk S, et al. Dronabinol is a safe long-term treatment option for neuropathic pain patients. Eur Neurol. 2017;78(5\u20136):320\u20139. This study has the largest sample size of those investigating pure forms of THC and its analogues.","DOI":"10.1159\/000481089"},{"issue":"9","key":"1196_CR25","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jpain.2016.05.010","volume":"17","author":"B Wilsey","year":"2016","unstructured":"Wilsey B, et al. An exploratory human laboratory experiment evaluating vaporized cannabis in the treatment of neuropathic pain from spinal cord injury and disease. J Pain. 2016;17(9):982\u20131000.","journal-title":"J Pain"},{"issue":"1","key":"1196_CR26","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/pme.12569","volume":"16","author":"D Turcotte","year":"2015","unstructured":"Turcotte D, et al. Nabilone as an adjunctive to gabapentin for multiple sclerosis-induced neuropathic pain: a randomized controlled trial. Pain Med. 2015;16(1):149\u201359.","journal-title":"Pain Med"},{"key":"1196_CR27","unstructured":"\u2022 Arout CA, et al. A placebo-controlled investigation of the analgesic effects, abuse liability, safety and tolerability of a range of oral cannabidiol doses in healthy humans. Br J Clin Pharmacol. 2022;88(1):347\u201355. This is the most recent study (at the time of writing) investigating dose dependency in CBD treatment."},{"issue":"5","key":"1196_CR28","doi-asserted-by":"crossref","first-page":"390","DOI":"10.2174\/1389201020666191202111534","volume":"21","author":"DH Xu","year":"2020","unstructured":"Xu DH, et al. The effectiveness of topical cannabidiol oil in symptomatic relief of peripheral neuropathy of the lower extremities. Curr Pharm Biotechnol. 2020;21(5):390\u2013402.","journal-title":"Curr Pharm Biotechnol"},{"issue":"7","key":"1196_CR29","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1002\/j.1532-2149.2013.00445.x","volume":"18","author":"M Serpell","year":"2014","unstructured":"Serpell M, et al. A double-blind, randomized, placebo-controlled, parallel group study of thc\/cbd spray in peripheral neuropathic pain treatment. Eur J Pain. 2014;18(7):999\u20131012.","journal-title":"Eur J Pain"},{"issue":"1","key":"1196_CR30","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.jpainsymman.2013.02.018","volume":"47","author":"ME Lynch","year":"2014","unstructured":"Lynch ME, Cesar-Rittenberg P, Hohmann AG. A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain. J Pain Symptom Manage. 2014;47(1):166\u201373.","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"1196_CR31","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s00415-012-6739-4","volume":"260","author":"RM Langford","year":"2013","unstructured":"Langford RM, et al. A double-blind, randomized, placebo-controlled, parallel-group study of thc\/cbd oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis. J Neurol. 2013;260(4):984\u201397.","journal-title":"J Neurol"},{"key":"1196_CR32","doi-asserted-by":"crossref","unstructured":"\u2022 Zubcevic K, et al. Oral capsules of tetra-hydro-cannabinol (thc), cannabidiol (cbd) and their combination in peripheral neuropathic pain treatment. Eur J Pain. 2022. This study compares pure forms of cannabinoids (CBD and THC) with using them in combination for peripheral neuropathic pain.","DOI":"10.1002\/ejp.2072"},{"issue":"4","key":"1196_CR33","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1002\/cpt.2016","volume":"109","author":"L Eibach","year":"2021","unstructured":"Eibach L, et al. Cannabidivarin for hiv-associated neuropathic pain: a randomized, blinded, controlled clinical trial. Clin Pharmacol Ther. 2021;109(4):1055\u201362.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"1196_CR34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.neurol.2018.09.016","volume":"175","author":"D Bouhassira","year":"2019","unstructured":"Bouhassira D. Neuropathic pain: definition, assessment and epidemiology. Revue Neurologique. 2019;175(1):16\u201325.","journal-title":"Revue Neurologique"},{"issue":"1","key":"1196_CR35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1089\/can.2018.0027","volume":"4","author":"GA Tyree","year":"2019","unstructured":"Tyree GA, et al. A cost-effectiveness model for adjunctive smoked cannabis in the treatment of chronic neuropathic pain. Cannabis Cannabinoid Res. 2019;4(1):62\u201372.","journal-title":"Cannabis Cannabinoid Res"},{"key":"1196_CR36","doi-asserted-by":"crossref","unstructured":"Wiffen PJ, et al. Gabapentin for acute and chronic pain. Cochrane Database Syst Rev. 2005;(3):CD005452.","DOI":"10.1002\/14651858.CD005452"},{"key":"1196_CR37","doi-asserted-by":"crossref","unstructured":"Wiffen P, et al. Anticonvulsant drugs for acute and chronic pain. Cochrane Database Syst Rev. 2000;(3):CD001133.","DOI":"10.1002\/14651858.CD001133"},{"key":"1196_CR38","unstructured":"Prostran M. Cannabinoids and pain: new insights from old molecules. Mech New Targets Treat Chr Pain. 2020."},{"key":"1196_CR39","first-page":"103","volume":"103","author":"P Morales","year":"2017","unstructured":"Morales P, Hurst DP, Reggio PH. Molecular targets of the phytocannabinoids: a complex picture. Prog Chem Org Nat Prod. 2017;103:103\u201331.","journal-title":"Prog Chem Org Nat Prod"},{"issue":"12","key":"1196_CR40","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1002\/sim.6848","volume":"35","author":"M \u017bebrowska","year":"2016","unstructured":"\u017bebrowska M, Posch M, Magirr D. Maximum type i error rate inflation from sample size reassessment when investigators are blind to treatment labels. Stat Med. 2016;35(12):1972\u201384.","journal-title":"Stat Med"},{"key":"1196_CR41","doi-asserted-by":"crossref","unstructured":"Jakowiecki J, et al. Allosteric modulation of the cb1 cannabinoid receptor by cannabidiol-a molecular modeling study of the n-terminal domain and the allosteric-orthosteric coupling. Mol. 2021;26(9).","DOI":"10.3390\/molecules26092456"},{"issue":"20","key":"1196_CR42","doi-asserted-by":"crossref","first-page":"4790","DOI":"10.1111\/bph.13250","volume":"172","author":"RB Laprairie","year":"2015","unstructured":"Laprairie RB, et al. Cannabidiol is a negative allosteric modulator of the cannabinoid cb1 receptor. Br J Pharmacol. 2015;172(20):4790\u2013805.","journal-title":"Br J Pharmacol"},{"issue":"3","key":"1196_CR43","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1139\/h05-018","volume":"31","author":"JL Wirch","year":"2006","unstructured":"Wirch JL, et al. Cold pressor test protocol to evaluate cardiac autonomic function. Appl Physiol Nutr Metab. 2006;31(3):235\u201343.","journal-title":"Appl Physiol Nutr Metab"},{"issue":"3","key":"1196_CR44","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/bph.12321","volume":"170","author":"TD Hill","year":"2013","unstructured":"Hill TD, et al. Cannabidivarin-rich cannabis extracts are anticonvulsant in mouse and rat via a cb1 receptor-independent mechanism. Br J Pharmacol. 2013;170(3):679\u201392.","journal-title":"Br J Pharmacol"},{"issue":"9","key":"1196_CR45","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1002\/ejp.2016","volume":"26","author":"DE Sepulveda","year":"2022","unstructured":"Sepulveda DE, et al. Cannabigerol (cbg) attenuates mechanical hypersensitivity elicited by chemotherapy-induced peripheral neuropathy. Eur J Pain. 2022;26(9):1950\u201366.","journal-title":"Eur J Pain"},{"key":"1196_CR46","first-page":"1","volume-title":"Xpharm: The comprehensive pharmacology reference","author":"DB Bylund","year":"2007","unstructured":"Bylund DB. Alpha-2 adrenoceptors*. In: Enna SJ, Bylund DB, editors. Xpharm: The comprehensive pharmacology reference. New York: Elsevier; 2007. p. 1\u20139."},{"key":"1196_CR47","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2022.108693","volume":"107","author":"A Kumar Kalvala","year":"2022","unstructured":"Kumar Kalvala A, et al. Role of cannabidiol and tetrahydrocannabivarin on paclitaxel-induced neuropathic pain in rodents. Int Immunopharmacol. 2022;107: 108693.","journal-title":"Int Immunopharmacol"},{"issue":"2","key":"1196_CR48","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/sj.bjp.0707486","volume":"153","author":"KL Wright","year":"2008","unstructured":"Wright KL, Duncan M, Sharkey KA. Cannabinoid cb2 receptors in the gastrointestinal tract: a regulatory system in states of inflammation. Br J Pharmacol. 2008;153(2):263\u201370.","journal-title":"Br J Pharmacol"},{"issue":"5","key":"1196_CR49","first-page":"366","volume":"6","author":"J Corroon","year":"2021","unstructured":"Corroon J. Cannabinol and sleep: separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366\u201371.","journal-title":"Cannabis Cannabinoid Res"},{"key":"1196_CR50","unstructured":"Coffman K, Neroulias N.\u00a0Washington first states to legalize recreational pot. 2012; Accessed 30 Apr 2023. Available from: https:\/\/www.reuters.com\/article\/us-usa-marijuana-legalization-idUSBRE8A602D20121107."}],"container-title":["Current Pain and Headache Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-023-01196-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11916-023-01196-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11916-023-01196-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,12]],"date-time":"2024-03-12T14:52:39Z","timestamp":1710255159000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11916-023-01196-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,14]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["1196"],"URL":"https:\/\/doi.org\/10.1007\/s11916-023-01196-1","relation":{},"ISSN":["1531-3433","1534-3081"],"issn-type":[{"value":"1531-3433","type":"print"},{"value":"1534-3081","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,14]]},"assertion":[{"value":"23 November 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethical approval was not required for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights"}},{"value":"The authors declare that they have no financial or non-financial competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}